Clinical-Stage Biotech · Life Sciences · San Francisco, CA · 10 weeks
R&D portfolio analytics built across 8 programs
A clinical-stage biotech with eight active programs and $340M in pipeline lacked a consistent way to track R&D performance. Each team used separate spreadsheets, leading to conflicting status reports for the board. We developed a centralized analytics platform that standardized program tracking, delivering one clear view of pipeline value and risk for leadership.
Challenge
Eight program teams each tracked milestones, spending, and success chances in their own spreadsheet format. The CFO’s team spent three weeks manually reconciling data for board reports, which program leads often challenged. This inconsistent reporting left the board unable to answer investor questions reliably.
Outcome
We cut board reporting time from three weeks to two days by standardizing data inputs. After four weeks aligning program leads on the unified data model, they fully adopted it. For the first time, investor presentations used consistent metrics approved by the board. The CFO leveraged portfolio analytics to pinpoint $18M in R&D spend that could be reallocated.
Results
- 3 weeks to 2 days Board reporting preparation time
- $18M R&D spend reallocation opportunities identified
- 8 programs Unified under single portfolio data model
- 100% Program lead acceptance of unified data model
We had 8 programs, each reporting differently, so the board couldn’t really compare them. Investors were getting uneasy. Thinklytics created a unified portfolio view in 10 weeks. Right away, the CFO spotted $18 million we could reallocate.